Modality
siRNA
MOA
KIF18Ai
Target
IL-23
Pathway
Neuroinflam
ALSWet AMDBreast Ca
Development Pipeline
Preclinical
Jul 2018
→ Aug 2031
PreclinicalCurrent
NCT06600571
944 pts·Breast Ca
2024-11→2031-08·Active
NCT05387238
2,894 pts·ALS
2018-07→2026-08·Completed
3,838 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-08-215mo awayInterim· ALS
2031-08-235.4y awayInterim· Breast Ca
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Preclinical
Complet…
Preclinical
Active
Catalysts
Interim
2026-08-21 · 5mo away
ALS
Interim
2031-08-23 · 5.4y away
Breast Ca
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06600571 | Preclinical | Breast Ca | Active | 944 | MRD |
| NCT05387238 | Preclinical | ALS | Completed | 2894 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 |